Optimizing Oral Contraceptives: Role of Immediate Release Formulations in Reproductive Health

Shivshankar Nagrik, Ashwini Verulkar , Aishwarya Ade , Rutuja Gaikwad , Mayuri Shelke , Khushbu Akturkar , Snehal Dethe , Sakshi Tupe , Prachi Jumale , Mohini Kale , Janhavi Gadhe , Kalyani Deshpande , Vaishnavi Sarode , Vaishnavi Puri , Monika Girhe , Nikhil Wagh, Pallavi Mangulkar,

doi:10.5281/zenodo.15818035

Review Paper | Open Access
Volume 02 | Issue 07 | Article Id IJSRT/250307009

Optimizing Oral Contraceptives: Role of Immediate Release Formulations in Reproductive Health
Shivshankar Nagrik* ¹ Ashwini Verulkar ² Aishwarya Ade ² Rutuja Gaikwad ² Mayuri Shelke ² Khushbu Akturkar ² Snehal Dethe ² Sakshi Tupe ² Prachi Jumale ² Mohini Kale ² Janhavi Gadhe ² Kalyani Deshpande ³ Vaishnavi Sarode ⁴ Vaishnavi Puri ⁵ Monika Girhe ⁶ Nikhil Wagh ⁶ Pallavi Mangulkar ⁷

Abstract

Oral contraceptive drugs are a cornerstone of reproductive healthcare, offering reliable and reversible birth control through hormonal modulation. This comprehensive review delves into the design and development of immediate release (IR) dosage forms for oral contraceptives, focusing on their pharmacological, formulation, and regulatory perspectives. IR tablets, commonly used in both progestin-only pills (POPs) and combined oral contraceptives (COCs), are engineered to ensure rapid disintegration and absorption of active pharmaceutical ingredients, such as ethinylestradiol and levonorgestrel. The review elaborates on key formulation strategies, including the selection of superdisintegrants, solubility and permeability enhancement techniques, and modern excipient technologies that support bioavailability and patient compliance. It discusses the challenges associated with IR formulations, such as strict adherence requirements, fluctuations in plasma hormone levels, and susceptibility to first-pass metabolism. Further emphasis is placed on the impact of manufacturing techniques like direct compression and granulation on dosage performance and quality control. Regulatory frameworks provided by the USFDA, EMA, and CDSCO are explored, with attention to bioequivalence, dissolution testing, and pharmacovigilance. The role of in vitro-in vivo correlation (IVIVC) is also addressed, highlighting its relevance in bridging laboratory findings with clinical efficacy. The review concludes by identifying opportunities for innovation in formulation science to enhance the safety, effectiveness, and accessibility of IR oral contraceptives, ultimately supporting better reproductive health outcomes globally.

Keywords

Oral contraceptives, Progestin-only pills, Combined oral contraceptives, bioavailability, Superdisintegrants, Regulatory guidelines

Introduction

Oral contraceptives, commonly known as birth control pills, are among the most widely used methods of reversible contraception globally. These medications primarily function through the modulation of female reproductive hormones to prevent ovulation, alter cervical mucus viscosity, and hinder endometrial implantation (1). They are categorized into two main types: combined oral contraceptives (COCs), which contain both estrogen (typically ethinylestradiol) and a progestin, and progestin-only pills (POPs), which contain only a progestin such as norethindrone or levonorgestrel (2). Since their introduction in the 1960s, oral contraceptives have undergone significant evolution, transitioning from high-dose formulations to more refined low-dose and ultralow-dose regimens, reducing adverse effects while maintaining efficacy (3). Their widespread adoption is attributed to their ease of administration, non-invasiveness, and additional non-contraceptive benefits such as menstrual regulation, acne control, and reduced risk of certain cancers (4). According to the World Health Organization (WHO), oral contraceptives are included in the Model List of Essential Medicines, reflecting their importance in public health systems worldwide (5). Despite their popularity, their effectiveness relies heavily on daily compliance, and missed doses can significantly reduce contraceptive efficacy, increasing the risk of unintended pregnancy. Immediate release (IR) dosage forms are designed to disintegrate and release their active pharmaceutical ingredients (APIs) quickly after oral administration. In the context of oral contraceptives, immediate release tablets are the standard delivery form, ensuring rapid absorption and consistent plasma hormone levels, which are critical for ovulation suppression (6). These formulations are engineered to maximize bioavailability by ensuring the drug dissolves promptly in the gastrointestinal tract, typically within 30 minutes of ingestion (7). The pharmacokinetics of IR oral contraceptives show rapid systemic absorption, usually achieving peak plasma concentrations within 1–2 hours for both ethinylestradiol and progestins like levonorgestrel (8). This rapid onset is particularly vital in start-of-cycle dosing, emergency contraception, and for maintaining hormonal consistency in daily regimens. Immediate release formulations are also advantageous in terms of manufacturing and patient acceptability, as they are generally small in size, easy to swallow, and costeffective to produce. Moreover, IR tablets facilitate fixed-dose combinations, allowing multiple hormones to be administered in a single pill, optimizing treatment adherence and hormonal synergy (9). Despite these advantages, IR forms also present challenges such as shorter duration of action, necessitating strict adherence to daily intake schedules, and variability in absorption due to food or gastrointestinal conditions. This comprehensive review is dedicated to exploring the multifaceted scientific, technological, and regulatory dimensions of immediate release (IR) dosage forms as applied in oral contraceptive therapy. A primary focus is placed on providing a detailed understanding of the formulation principles that govern the development of IR oral contraceptive tablets. The review critically examines the pharmacokinetic and pharmacodynamic characteristics of the commonly employed hormonal agents in these formulations, shedding light on how these profiles influence therapeutic outcomes. Furthermore, this work evaluates the clinical performance of immediate release formulations in terms of their ability to ensure reliable contraceptive efficacy, while also acknowledging inherent limitations such as dosing frequency and hormonal fluctuations. An important component of the review is the examination of recent technological innovations, including advancements in excipient development, tablet manufacturing techniques, and novel drug delivery approaches that aim to optimize the effectiveness and consistency of IR contraceptives. In addition to the technological and scientific perspectives, the review addresses the regulatory landscape surrounding IR oral contraceptives. This includes a discussion on critical elements such as quality control measures, standards for establishing bioequivalence, and strategies to improve patient adherence, all of which are essential for the successful deployment of these products in clinical settings. The review concludes by identifying key knowledge gaps within the current body of research and practice. It emphasizes the need for continued investigation and innovation to refine IR formulations further. These future directions aim to enhance the overall efficacy, safety profile, and user acceptability of oral contraceptive regimens, ultimately contributing to more effective reproductive health management.

2. Classification and Types of Oral Contraceptive Drugs

Oral contraceptive drugs are broadly classified based on their hormonal composition and therapeutic indications. The two principal categories are progestin-only pills (POPs) and combined oral contraceptives (COCs). Understanding their pharmacology, mechanism of action, and relevance to immediate release (IR) formulations is essential for optimizing contraceptive therapy.

2.1 Progestin-Only Pills

Progestin-only pills, often referred to as “mini-pills,” contain a single active hormone—a synthetic progestin, such as norethindrone, desogestrel, or levonorgestrel. Unlike combined formulations, POPs do not contain estrogen and are therefore preferred in individuals who are estrogen-intolerant, breastfeeding, or at risk for cardiovascular complications (10). These formulations work primarily by thickening cervical mucus, thereby inhibiting sperm penetration. Some POPs, particularly those containing desogestrel at higher doses, can suppress ovulation, although this is not consistent across all progestin types (11). POPs are typically formulated as immediate release tablets to ensure rapid and consistent plasma levels, given their short half-lives and narrow therapeutic windows. A key challenge with POPs is the requirement for strict adherence, as missing a dose by more than 3 hours may compromise contraceptive effectiveness (12). This underscores the need for high-performance IR formulations with robust dissolution profiles and reliable bioavailability.

2.2 Combined Oral Contraceptives (COCs)

COCs contain both an estrogen (usually ethinylestradiol) and a progestin (such as levonorgestrel, norethindrone acetate, or drospirenone). These formulations exert multiple effects on the reproductive axis, providing a more comprehensive contraceptive mechanism compared to POPs (13). The estrogen component suppresses the secretion of follicle-stimulating hormone (FSH), preventing follicular development, while the progestin inhibits the luteinizing hormone (LH) surge, thereby blocking ovulation. Additionally, they alter the endometrial lining and cervical mucus, further reducing the likelihood of fertilization and implantation (14). COCs are widely used due to their high efficacy (failure rates <1% with perfect use), regular menstrual bleeding patterns, and non-contraceptive benefits, such as acne reduction and lower risk of ovarian and endometrial cancers (15). These tablets are almost universally produced as immediate release formulations to ensure rapid hormone absorption, essential for consistent endocrine suppression throughout the cycle.

2.3 Mechanism of Action

Both POPs and COCs utilize hormonal modulation to prevent pregnancy. The mechanisms differ slightly based on the composition but broadly include the following pathways:

Ovulation suppression: COCs consistently suppress ovulation, while certain POPs achieve partial or inconsistent suppression.

Cervical mucus thickening: Both COCs and POPs cause the cervical mucus to become viscous, forming a barrier to sperm.

Endometrial alteration: The endometrial lining is rendered inhospitable for embryo implantation.

Fallopian tube motility: Hormonal changes may also impact tubal transport of ova and sperm (16). Immediate release dosage forms play a pivotal role in facilitating these mechanisms by ensuring quick systemic absorption and timely plasma peaks, especially important for progestins with short half-lives.

2.4 Selection Criteria for Immediate Release Formulations

Formulating an oral contraceptive as an immediate release tablet is guided by several criteria:

Pharmacokinetics of the drug: Drugs with rapid absorption requirements, short halflives, and time-sensitive actions (e.g., desogestrel) are suited for IR formulations (17).

Onset of action: Rapid action is needed to establish hormonal levels for ovulation suppression or emergency contraception.
Patient compliance: IR tablets are usually small, convenient, and inexpensive, promoting better adherence in daily dosing regimens.
Drug stability: Hormonal APIs used in contraceptives are generally stable in solid dosage forms, making IR tablets ideal for long shelf life and ease of storage.
Manufacturability and scalability: IR tablets are compatible with large-scale, costeffective manufacturing techniques, making them widely available in both branded and generic markets.
Regulatory standards: Regulatory authorities, such as the FDA and EMA, require demonstration of bioequivalence and consistent dissolution for IR products, ensuring therapeutic interchangeability (18).

Thus, IR formulations are favored for most oral contraceptive drugs due to their effectiveness in maintaining hormonal homeostasis, predictable pharmacodynamics, and ease of patient use.

3. Advantages and Limitations Of Immediate Release Formulations

3.1 Benefits of Immediate Release Formulations

Immediate release (IR) dosage forms are the standard in oral contraceptive therapy due to their pharmacokinetic efficiency, user convenience, and cost-effectiveness. These formulations are designed to disintegrate rapidly in the gastrointestinal tract, allowing for quick absorption of the active pharmaceutical ingredients (APIs). This rapid onset of action plays a crucial role in ensuring the effectiveness and reliability of hormonal contraceptives.

Faster Onset of Action

One of the most prominent advantages of IR dosage forms is their fast-pharmacological onset, which is especially beneficial in contraceptive regimens requiring timely hormonal modulation. After ingestion, IR tablets typically release their contents within 30 minutes, resulting in peak plasma concentrations of hormones like ethinylestradiol and levonorgestrel within 1 to 2 hours (19). This rapid systemic availability ensures that hormone levels are sufficient to:

Suppress ovulation
Thicken cervical mucus
Alter endometrial receptivity

Such prompt action is particularly critical in start-of-cycle administration and emergency contraceptive situations, where delays in hormone absorption could reduce effectiveness (20).

Improved Compliance and Convenience

IR formulations also enhance patient adherence, which is vital for contraceptive efficacy. These tablets are typically:

Small in size
Easy to swallow
Free from complicated administration techniques

Their once-daily dosing regimen, combined with predictable onset and offset of action, makes them user-friendly and suitable for long-term use, especially in low-resource settings where healthcare follow-up may be infrequent (21). Unlike extended-release formulations that may require specialized manufacturing or variable absorption profiles, IR tablets offer a straightforward therapeutic approach that aligns with diverse user needs and lifestyles.

Cost-Effectiveness and Manufacturing Simplicity

Immediate release dosage forms are inexpensive to manufacture, making them widely accessible. Their formulation technology is well-established, involving conventional wet granulation, direct compression, or dry granulation methods. This contributes to the low production cost, which is a significant advantage in public health programs aimed at increasing contraceptive access (22). Additionally, IR formulations provide flexibility in hormonal dosing, facilitating the development of low-dose combinations, multiphasic regimens, or generic equivalents without compromising therapeutic outcomes.

Rapid Reversibility

Another unique benefit of IR oral contraceptives is their reversibility upon discontinuation. Since the active hormones are cleared relatively quickly from the body, normal menstrual cycles and fertility often return within a few weeks to months after cessation of use (23). This makes IR contraceptives highly suitable for women planning for short-term contraception or transitioning between reproductive planning stages

3.2 Challenges of Immediate Release Formulations

While immediate release (IR) dosage forms are the most common and practical formulation for oral contraceptives, they are not without limitations. Challenges such as fluctuating plasma hormone levels, strict dosing schedules, and patient adherence concerns can impact their overall effectiveness and patient satisfaction. These drawbacks must be understood to improve formulation strategies and contraceptive outcomes.

Fluctuating Plasma Hormone Levels

One of the most significant challenges of IR contraceptive formulations is the rapid absorption and elimination of the active hormones. This can result in peaks and troughs in plasma concentrations, which may compromise consistent endocrine suppression, especially if doses are missed or taken irregularly (24). For example, ethinylestradiol and levonorgestrel, two commonly used hormones in COCs, reach peak plasma concentrations within 1–2 hours of ingestion and then undergo a rapid decline due to hepatic metabolism and biliary excretion (25). These fluctuations can:

Reduce the margin of safety for ovulation suppression.
Increase the risk of breakthrough ovulation, particularly in low-dose formulations.
Cause hormonal side effects such as nausea, breast tenderness, or mood changes due to high peak concentrations.

Maintaining steady-state hormone levels is more difficult with IR formulations than with extended-release systems, making daily dosing consistency crucial for efficacy.

Strict Dosing Schedule and Compliance Issues

Another major limitation is the requirement for strict adherence to the daily dosing schedule. Missing a single dose—especially with progestin-only pills (POPs)—can significantly compromise contraceptive effectiveness due to the short half-life of these hormones (26). Most POPs must be taken within the same 3-hour window each day, failing which backup contraception is recommended.

This rigidity in dosing introduces several issues:

Increased user burden, particularly for individuals with irregular routines.
Higher likelihood of missed pills, which is a common reason for contraceptive failure.
Greater dependence on reminder systems, apps, or counseling for adherence.

Studies have shown that real-world failure rates of oral contraceptives are significantly higher than those in clinical trials, primarily due to poor compliance with IR regimens (27).

First-Pass Metabolism and Drug Interactions

Immediate release contraceptives are also susceptible to first-pass hepatic metabolism, which can reduce bioavailability and alter therapeutic outcomes. This is particularly relevant in individuals taking enzyme-inducing medications (e.g., rifampin, phenytoin), which can increase clearance of contraceptive hormones and lower plasma levels below the threshold needed for ovulation suppression (28). Furthermore, gastrointestinal disturbances such as vomiting or diarrhea can reduce absorption of IR tablets, again leading to transient reductions in hormone levels and risk of pregnancy.

Lack of Hormone Reservoir Effect

IR formulations release the entire drug content quickly after ingestion, without providing a reservoir effect that could maintain hormone levels for extended periods. In contrast, extended-release or long-acting delivery systems like intrauterine devices (IUDs) or implants maintain therapeutic levels more consistently and are less susceptible to user error (29). This lack of sustained release from IR tablets makes them inherently more prone to fluctuations and failures if not taken precisely as directed.

4. Formulation Strategies for Immediate Release Oral Contraceptives

4.1 Choice of Excipients and Carriers

The formulation of immediate release (IR) oral contraceptives requires careful selection of excipients and carriers to ensure rapid drug release, stability, and bioavailability. Excipients play a critical role in the pharmacokinetics of the active pharmaceutical ingredients (APIs), influencing their disintegration, dissolution, and absorption in the gastrointestinal tract. Therefore, the excipients chosen must not only be compatible with the active drug but also help achieve optimal therapeutic effects.

Table 1: Common Excipients Used in Immediate Release Oral Contraceptive Formulations and Their Functional Roles

Excipient Class	Example(s)	Primary Function(s)	Remarks
Binders	Polyvinylpyrrolidone (PVP), Microcrystalline Cellulose	Provide mechanical strength; aid in tablet cohesion and disintegration	PVP forms strong films and promotes rapid disintegration; cellulose derivatives also function as disintegrants
Disintegrants	Croscarmellose Sodium, Sodium Starch Glycolate	Facilitate rapid tablet breakdown and drug release	Superdisintegrants that swell upon contact with water, ensuring efficient disintegration and faster hormone absorption
Fillers/Diluents	Lactose, Mannitol	Add bulk to tablets; improve swallowability and mechanical properties	Lactose ensures uniform tablet size; mannitol enhances palatability, often used in chewable contraceptives
Solubilizing Agents	Cyclodextrins, Polysorbates	Improve solubility and dissolution of poorly soluble active ingredients	Cyclodextrins form inclusion complexes with hydrophobic drugs; polysorbates enhance absorption by acting as surfactants
Lubricants	Magnesium Stearate, Stearic Acid	Reduce friction during tablet compression; prevent sticking to equipment	Essential for smooth manufacturing processes; help ensure uniformity and quality of the final dosage form

Choice of Carriers

Table 2: Selection of Carriers in Immediate Release Oral Contraceptive Formulations and Their Functional Contributions

Carrier Type	Example(s)	Function in Formulation	Remarks
Polymers	Hydroxy propyl methylcellulose (HPMC)	Enhance disintegration; aid in modifying dissolution rate	HPMC supports rapid disintegration while enabling consistent drug release, especially beneficial for poorly soluble compounds
Soluble Supports	Gelatin	Improve solubility and bioavailability	Water-soluble carrier that enhances dissolution and absorption, leading to increased contraceptive effectiveness

4.2 Direct Compression and Granulation Techniques

The manufacturing process of immediate release (IR) oral contraceptives significantly influences their quality, bioavailability, and patient compliance. Among various formulation strategies, direct compression and granulation techniques are two of the most common approaches used in the production of oral contraceptive tablets. These methods ensure the desired drug release profile, tablet integrity, and uniformity in dosage. This section elaborates on both techniques and their relevance to IR oral contraceptive formulations.

Direct Compression

Direct compression is a widely adopted technique in the pharmaceutical industry for the production of tablets. This method involves the compaction of powder blends directly into tablets without the need for prior wetting or drying, making it a cost-effective and timeefficient process. Direct compression is particularly advantageous in the formulation of immediate release oral contraceptives due to its simplicity and ability to maintain the physical stability of sensitive active pharmaceutical ingredients (APIs).

Advantages of Direct Compression

Simplicity and Cost-Effectiveness: Direct compression does not require the use of solvents, binders, or significant amounts of processing equipment. This makes the technique cost-effective, reducing overall manufacturing costs for oral contraceptive tablets (36).
Preservation of API Stability: Since no heat or solvents are involved, direct compression is ideal for APIs that are sensitive to moisture, temperature, or chemical degradation. This is particularly important for hormonal drugs used in oral contraceptives, which need to remain stable during manufacturing and storage (37).
Faster Production Time: The direct compression process is generally faster compared to traditional wet granulation methods, which involves multiple steps like drying and screening. This results in a quicker turnaround time for the production of oral contraceptive tablets (38).

Challenges and Considerations in Direct Compression

Need for Suitable Excipients: The formulation must include excipients that can flow well, compress uniformly, and ensure tablet cohesion without the need for additional binders or granulation steps. Common excipients used in direct compression include microcrystalline cellulose, lactose, and starch-based excipients (39).
Limited to Certain Drug Properties: Not all drugs are suitable for direct compression due to their poor flow properties, inconsistent particle size, or low compressibility. In such cases, granulation techniques may be preferred.

Granulation Techniques

Granulation involves the aggregation of primary powder particles to form granules, which are then compressed into tablets. There are two primary types of granulation techniques used in the manufacturing of IR oral contraceptives: wet granulation and dry granulation. Granulation techniques are particularly useful when the drug has poor flow properties or requires a controlled particle size distribution for uniformity.

Wet Granulation

In wet granulation, a liquid binder is added to the powder blend to form a damp mass. This mass is then passed through a screen to form granules, which are dried and blended with additional excipients before compression into tablets. Wet granulation is commonly employed for oral contraceptives when APIs require improved flowability, better compression, and consistent dissolution profiles.

Advantages of Wet Granulation

Enhanced Uniformity: Wet granulation helps in achieving uniform distribution of active pharmaceutical ingredients (APIs), improving dose uniformity in each tablet (40).
Improved Flow and Compressibility: The granulation process improves the flowability and compressibility of the powder blend, which can be beneficial for drugs that are not ideal for direct compression due to their poor powder properties.

Challenges of Wet Granulation

Time and Resource Intensive: The wet granulation process requires several stages such as wet mixing, drying, and screening, which increase manufacturing time and costs (41).
Stability Concerns: The use of heat and moisture during the wet granulation process can lead to the degradation or instability of certain drugs, particularly sensitive APIs used in oral contraceptives.

Dry Granulation

In dry granulation, the powder blend is compacted under high pressure to form granules without the use of a binder or liquid. This method is used when the API is sensitive to heat or moisture and cannot withstand the conditions of wet granulation.

Advantages of Dry Granulation

No Use of Solvents or Heat: Dry granulation eliminates the need for heat or moisture, making it suitable for heat-sensitive APIs. This is particularly relevant for oral contraceptives containing hormonal drugs, which are sensitive to temperature and humidity (42).
Reduced Process Time: Dry granulation involves fewer steps compared to wet granulation, offering a quicker manufacturing timeline.

Challenges of Dry Granulation

Limited to Certain Formulations: Dry granulation is not suitable for all drug formulations, especially those that require high binding or cohesive properties. In some cases, it may lead to poor granule formation, which can affect tablet quality.
Less Control Over Granule Size: Dry granulation may result in a broader particle size distribution compared to wet granulation, which could affect the uniformity of the drug release (43).

Applications in Immediate Release Oral Contraceptives

Both direct compression and granulation techniques are applicable to immediate release oral contraceptives depending on the formulation requirements.

Direct compression is more suitable for simple formulations where the active ingredient has good flow properties and compressibility. Many progestin-only and combined oral contraceptives with relatively stable active ingredients can be manufactured using direct compression (44).
Granulation is more beneficial when there is a need to modify the dissolution rate, improve uniformity, or address poor flow properties of the drug. Granulation can also be used for oral contraceptive tablets that require controlled release or those containing complex active ingredients that need more advanced formulation techniques (45).

4.3 Use of Superdisintegrants

Reference

Raviele KM. 4. Reproductive Health and the Practice of Gynecology. Catholic Witness in Health Care: Practicing Medicine in Truth and Love. 2017 Sep 15:105.
Bachmann G, Korner P. Bleeding patterns associated with non-oral hormonal contraceptives: a review of the literature. Contraception. 2009 Apr 1;79(4):247-58.
Barnett C, Hagemann C, Dinger J, Do Minh T, Heinemann K. Fertility and combined oral contraceptives–unintended pregnancies and planned pregnancies following oral contraceptive use–results from the INAS-SCORE study. The European Journal of Contraception & Reproductive Health Care. 2017 Jan 2;22(1):17-23.
Burkman RT. Oral contraceptives: current status. Clinical obstetrics and gynecology. 2001 Mar 1;44(1):62-72.
Piggott T, Moja L, Huttner B, Okwen P, Raviglione MC, Kredo T, Schünemann HJ. WHO Model list of essential medicines: Visions for the future. Bulletin of the World Health Organization. 2024 Aug 29;102(10):722.
Koren G, Pastuszak A, Ito S. Drugs in pregnancy. New England Journal of Medicine. 1998 Apr 16;338(16):1128-37.
Shah VP, Tsong Y, Sathe P, Liu JP. In vitro dissolution profile comparison—statistics and analysis of the similarity factor, f2. Pharmaceutical research. 1998 Jun; 15:889-96.
Stanczyk FZ. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Reviews in Endocrine and Metabolic Disorders. 2002 Sep; 3:211-24.
Martindale C. The complete drug references. Sweetman SC, editor. London: Pharmaceutical press; 2009 Mar.
Coelingh Bennink HJ, van Gennip FA, Gerrits MG, Egberts JF, Gemzell-Danielsson K, Kopp-Kallner H. Health benefits of combined oral contraceptives–a narrative review. The European Journal of Contraception & Reproductive Health Care. 2024 Mar 3;29(2):40-52.
Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF. 20 µg versus> 20 µg estrogen combined oral contraceptives for contraception. Cochrane Database of Systematic Reviews. 2013(8).
Sitruk-Ware R. New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs & aging. 2004 Nov; 21:865-83.
Burkman RT, Collins JA, Shulman LP, Williams JK. Current perspectives on oral contraceptive use. American journal of obstetrics and gynecology. 2001 Aug 1;185(2):S4-12.
Speroff L, Darney PD. A clinical guide for contraception. Lippincott Williams & Wilkins; 2011.
Raviele KM. 4. Reproductive Health and the Practice of Gynecology. Catholic Witness in Health Care: Practicing Medicine in Truth and Love. 2017 Sep 15:105.
Fraser IS. Non-contraceptive health benefits of intrauterine hormonal systems. Contraception. 2010 Nov 1;82(5):396-403.
Stanczyk FZ, Archer DF. Gestodene: a review of its pharmacology, potency and tolerability in combined contraceptive preparations. Contraception. 2014 Apr 1;89(4):242-52.
Wu F, Shah H, Li M, Duan P, Zhao P, Suarez S, Raines K, Zhao Y, Wang M, Lin HP, Duan J. Biopharmaceutics applications of physiologically based pharmacokinetic absorption modeling and simulation in regulatory submissions to the US Food and Drug Administration for new drugs. The AAPS Journal. 2021 Mar; 23:1-4.
Stanczyk FZ, Archer DF. Gestodene: a review of its pharmacology, potency and tolerability in combined contraceptive preparations. Contraception. 2014 Apr 1;89(4):242-52.
Bruisten SM, Nilsson-Ihrfelt E, Buhrman M, Ekselius L. TOXBASE. Emerg Med J. 2006 Aug; 23 (8): 614-7. PMID: 16858093 [PubMed-in process] 24: Team V, Markovic M. Internet advertising of artificial tanning in Australia. InOncol Nurs Forum 2006 Nov 3 (Vol. 33, No. 2, pp. 249-54).
Dinger J, Do Minh T, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large US cohort comparing progestogen and regimen. Obstetrics & Gynecology. 2011 Jan 1;117(1):33-40.
Martindale C. The complete drug reference. Sweetman SC, editor. London: Pharmaceutical press; 2009 Mar.
Hatcher RA. Contraceptive technology. Ardent Media; 2007.
Stanczyk FZ, Archer DF. Gestodene: a review of its pharmacology, potency and tolerability in combined contraceptive preparations. Contraception. 2014 Apr 1;89(4):242-52.
Kuhnz W, Hümpel M, Biere H, Gross D. Influence of repeated oral doses of ethinyloestradiol on the metabolic disposition of [13C2]-ethinyloestradiol in young women. European journal of clinical pharmacology. 1996 May; 50:231-5.
Goldenberg RL, Das AF, Meis PJ. Maternal±fetal medicine. Acta Obstet Gynecol Scand. 2001; 80:120-5.
Trussell J. Contraceptive failure in the United States. Contraception. 2004 Aug 1;70(2):89-96.
Back DJ, Orme ML. Pharmacokinetic drug interactions with oral contraceptives. Clinical pharmacokinetics. 1990 Jun; 18:472-84.
French R, Van Vliet H, Cowan F, Mansour D, Morris S, Hughes D, Robinson A, Proctor T, Summerbell C, Logan S, Helmerhorst F. Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy. The Cochrane database of systematic reviews. 2004;2004(3):CD001776.
Kolhe MH, Gilhotra RM, Asane GS. Development of capsule containing immediate release tablet and extended release floating tablet for monitoring release of atenolol. Research Journal of Pharmacy and Technology. 2021;14(4):2216-20.
Lachman L, Lieberman HA, Kanig JL. The theory and practice of industrial pharmacy. Philadelphia: Lea & Febiger; 1976.
Mahato RI, Narang AS. Pharmaceutical dosage forms and drug delivery: revised and expanded. CRC Press; 2017 Nov 22.
Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. Journal of pharmaceutical sciences. 1996 Oct;85(10):1017-25.
Rowe RC, Sheskey P, Quinn M. Handbook of pharmaceutical excipients. Libros Digitales-Pharmaceutical Press; 2009.
Vyas SP, Khar RK. Controlled drug delivery concepts and advances. Vallabh prakashan. 2002; 1:411-7.
Kamboj S, Mittal A, Kumawat M. Direct Compression: A Novel Approach to Tablet Formulation. J Pharm Bioallied Sci. 2012;4(1):9–15.
Dwivedi J, Sachan P, Wal P, Kosey S, Khan MM. Progressive journey of phytosomes: preparation, characterization, patents, clinical trials & commercial products. J Res Pharm. 2023 Sep 1;27(5):1687-733.
Iqubal MK, Singh PK, Shuaib M, Iqubal A, Singh M. Recent advances in direct compression technique for pharmaceutical tablet formulation. Int J Pharm Res & Devel. 2014;6(1):49-57.
Basudkar V, Gharat SA, Momin MM, Shringarpure M. A review of anti-aging nanoformulations: Recent developments in excipients for nanocosmeceuticals and regulatory guidelines. Critical Reviews™ in Therapeutic Drug Carrier Systems. 2022;39(3).
Parikh DM. Handbook of pharmaceutical granulation technology. Drugs and the pharmaceutical sciences. 2005;81.
Bansal AK, Choi J, Simonelli AP. Granulation Techniques: Wet Granulation. In: Banker GS, Anderson NR, editors. Tablets. Vol. 1. New York: Marcel Dekker; 1986. p. 211–237.
Parikh DM. Handbook of pharmaceutical granulation technology. Drugs and the pharmaceutical sciences. 2005;81.
Almeida-Naranjo CE, Guerrero VH, Villamar-Ayala CA. Emerging contaminants and their removal from aqueous media using conventional/non-conventional adsorbents: a glance at the relationship between materials, processes, and technologies. Water. 2023 Apr 21;15(8):1626.
Basciani S, Porcaro G. Counteracting side effects of combined oral contraceptives through the administration of specific micronutrients. European Review for Medical & Pharmacological Sciences. 2022 Jul 1;26(13).
Saha SK, Joshi A, Singh R, Dubey K. Review of industrially recognized polymers and manufacturing processes for amorphous solid dispersion-based formulations. Pharmaceutical Development and Technology. 2023 Aug 9;28(7):678-96.
Okur ME, Karantas ID, Okur NU, Siafaka PI. Hypertension in 2017: Update in treatment and pharmaceutical innovations. Current Pharmaceutical Design. 2017 Dec 1;23(44):6795-814.
Kalasz H, Antal I. Drug excipients. Current medicinal chemistry. 2006 Sep 1;13(21):2535-63.
Singh VK, Singh U, Mishra A, Chandra D, Sahu R. A Review on Mouth Dissolving Tablet Using Different Super Disintegrant. World J. Pharm. Res. 2014 Jul 13;3(7):755-91.
Lasekan A, Koganti S, et al. Use of disintegrants in tablets: A comprehensive review. Drug Dev Ind Pharm. 2014;40(2):183-191.
Qureshi MS, Zafar F, Ali H, Hameed K, Mallick N, Khan S, Baloch SA. Superdisintegrant On Disintegrant And Dissolution: A Review on Influence. The Professional Medical Journal. 2016 Oct 10;23(10):1167-70.
Panda S, Latha V, Pattnaik S, Maharana L, Prasad R. An update on various excipients employed for orodispersible tablets with a special focus on superdisintegrants. International Journal of Pharmaceutical and Clinical Research. 2015;7(6):440-9. Ghosh S, et al. Use of superdisintegrants in the development of fast-disintegrating tablets. Pharma Times. 2014;46(9):11–14.
Panda S, Latha V, Pattnaik S, Maharana L, Prasad R. An update on various excipients employed for orodispersible tablets with a special focus on superdisintegrants. International Journal of Pharmaceutical and Clinical Research. 2015;7(6):440-9.
Kar¹ M, Chourasiya Y, Maheshwari R. Current Developments in Excipient Science: Implication of Quantitative Selection of Each Excipient in. Basic Fundamentals of Drug Delivery. 2018 Nov 30:29. Martin A, Bustamante P, Chun A. Solid dispersions for enhanced solubility: A review. Drug Dev Ind Pharm. 1995;21(11):1259-1273.
Rashid M, Malik MY, Singh SK, Chaturvedi S, Gayen JR, Wahajuddin M. Bioavailability enhancement of poorly soluble drugs: the holy grail in pharma industry. Current Pharmaceutical Design. 2019 Mar 1;25(9):987-1020.Swain S, et al. Salt formation for enhancing the solubility of poorly soluble drugs. Int J Pharm Sci. 2011;10(3):44-49.
Singh V, Bansal K, Bhati H, Bajpai M. New insights into pharmaceutical nanocrystals for the improved topical delivery of therapeutics in various skin disorders. Current pharmaceutical biotechnology. 2024 Jul 1;25(9):1182-98. Ueda H, et al. Cyclodextrin complexes for solubility enhancement of lipophilic drugs. J Pharm Sci. 2010;99(2):925-931.
Peptu C, Humelnicu AC, Rotaru R, Fortuna ME, Patras X, Teodorescu M, Tamba BI, Harabagiu V. Chitosan?based drug delivery systems. Chitin and Chitosan: Properties and Applications. 2019 Dec 31:259-89.
Hwang J, et al. Fatty acids and surfactants in enhancing the intestinal permeability of poorly soluble drugs. J Pharm Sci. 2009;98(1):33-43.
Lau MH. Exploring new therapeutic properties from the encapsulation of pharmaceutical compounds within mesoporous silica particles (Doctoral dissertation, Macquarie University).
Debnath SK, Singh B, Agrawal N, Srivastava R. EPR-Selective Biodegradable Polymer-Based Nanoparticles for Modulating ROS in the Management of Cervical Cancer. InHandbook of Oxidative Stress in Cancer: Therapeutic Aspects 2022 Sep 29 (pp. 2863-2889). Singapore: Springer Nature Singapore.Jain K, et al. Microneedle technology for enhanced drug permeability in oral formulations. Drug Dev Ind Pharm. 2015;41(9):1371-1378.
Patel R, Patel G. Preparation and Characterization of a Novel Optimum Modified Liquisolid Compact to Enhance the Dissolution Profile of Mifepristone. Dissolution Technologies. 2023 Nov 1;30(4):238-44.
Coimbra AT. Biological properties of aromatic plants used in folk medicine: a focus on the essential oil of Thymus zygis (Doctoral dissertation, Universidade da Beira Interior (Portugal)).
Murakami T, Bodor E, Bodor N. Modulation of expression/function of intestinal P-glycoprotein under disease states. Expert Opinion on Drug Metabolism & Toxicology. 2020 Jan 2;16(1):59-78.
Omari DM, Akkam Y, Sallam A. Drug-excipient interactions: an overview on mechanisms and effects on drug stability and bioavailability. Annals of the Romanian Society for Cell Biology. 2021;25(4):8402-29.
Stewart SA, Domínguez-Robles J, Donnelly RF, Larrañeta E. Implantable polymeric drug delivery devices: classification, manufacture, materials, and clinical applications. Polymers. 2018 Dec 12;10(12): 1379.Harper J, et al. Bioavailability of ethinyl estradiol in different formulation types. Int J Pharm. 2010;398(1-2):16-22.
Pahwa R, Gupta N. Superdisintegrants in the development of orally disintegrating tablets: a review. International journal of pharmaceutical sciences and research. 2011 Nov 1;2(11): 2767.Young L, et al. Solubilizing agents in oral contraceptive formulations. Int J Pharm. 2014;460(1-2):1-9.
Gomaa E, Faisal MM. Formulation and in-vitro evaluation of Propranolol Hcl mucoadhesive vaginal beads for contraceptive purposes. Zagazig Journal of Pharmaceutical Sciences. 2023 Dec 1;32(2):59-67.
Salehi N, Kuminek G, Al-Gousous J, Sperry DC, Greenwood DE, Waltz NM, Amidon GL, Ziff RM, Amidon GE. Improving dissolution behavior and oral absorption of drugs with pH-dependent solubility using ph modifiers: a physiologically realistic mass transport analysis. Molecular Pharmaceutics. 2021 Aug 24;18(9):3326-41.
Yang X, Yang Y, Yu H, Zhou Y. Self-Assembled Polymers for Gastrointestinal Tract Targeted Delivery through the Oral Route: An Update. Polymers. 2023 Aug 25;15(17):3538.
Kalibala J, Pechere-Bertschi A, Desmeules J. Gender differences in cardiovascular pharmacotherapy—the example of hypertension: a mini review. Frontiers in pharmacology. 2020 May 6;11:564.Dimas F, et al. Impact of BMI on drug absorption in oral contraceptives. J Pharm Pharmacol. 2017;69(9):1290-1300.
Marchetti S, Schellens JH. Clinical relevance: drug–drug interactions, pharmacokinetics, pharmacodynamics, and toxicity. Drug Transporters: Molecular Characterization and Role in Drug Disposition. 2014 Aug 8:433-71.
Hulub? IP, Crecan-Suciu BD, P?unescu R, Miclu?ia IV. The link between sex hormones and depression over a woman's lifespan. Biomedical Reports. 2025 Feb 20;22(4):71.Patel RV, et al. Dissolution testing and bioavailability of oral contraceptives. J Pharm Sci. 2013;102(6):1894-1904.
Fadiran EO, Zhang L. Effects of sex differences in the pharmacokinetics of drugs and their impact on the safety of medicines in women. InMedicines for women 2014 Dec 18 (pp. 41-68). Cham: Springer International Publishing.
Gupta MD. Unravelling the Role of Microbiome and Escherichia coli as a Trigger for Inflammatory Bowel Disease With a Particular Focus on Crohn's Disease (Doctoral dissertation, The Australian National University (Australia)).
Shah D, Patil M, National PCOS Working Group. Consensus statement on the use of oral contraceptive pills in polycystic ovarian syndrome women in India. Journal of human reproductive sciences. 2018 Apr 1;11(2):96-118.Dimas F, et al. Metabolism of progestins in oral contraceptives: The role of hepatic enzymes. Contraception. 2012;85(4):412-419.
Osi B, Khoder M, Al-Kinani AA, Alany RG. Pharmaceutical, biomedical and ophthalmic applications of biodegradable polymers (BDPs): literature and patent review. Pharmaceutical Development and Technology. 2022 Mar 16;27(3):341-56. Rowland M, et al. Drug interactions and their impact on oral contraceptive efficacy. J Clin Pharm. 2013;53(5):1232-1240.
Tassi A, Londero AP, Xholli A, Lanzolla G, Bertozzi S, Savelli L, Prefumo F, Cagnacci A. Hormonal Contraception and Bone Metabolism: Emerging Evidence from a Systematic Review and Meta-Analysis of Studies on Post-Pubertal and Reproductive-Age Women. Pharmaceuticals. 2025 Jan 8;18(1):61.
Banjoko B. Environmental pharmacology–an overview. Pharmacol therapeut. 2014 Jul 2.
Mosorin ME. Metabolic effects of hormonal contraception in women with and without polycystic ovary syndrome.
Seghieri G, Franconi F, Campesi I. Why we need sex-gender medicine: The striking example of type 2 diabetes. Diabetology. 2022 Aug 11;3(3):460-9.
De Boer A, Van Hunsel F, Bast A. Adverse food–drug interactions. Regulatory Toxicology and Pharmacology. 2015 Dec 1;73(3):859-65.
Perkins MS. Investigating the mechanism of action of hormones used in hormone replacement therapy via estrogen receptor subtypes and the influence of the progesterone receptor (Doctoral dissertation, Stellenbosch: Stellenbosch University). Gupta S, et al. Effect of high-fat meals on the absorption of oral contraceptives. Clin Pharmacol Ther. 2015;97(2):101-107.
Ameer B, Weintraub RA. Drug interactions with grapefruit juice. Clinical pharmacokinetics. 1997 Aug;33(2):103-21. Lippert J, et al. Food interactions with contraceptive drugs: Current perspectives. Ther Drug Monit. 2016;38(4):462-469.
Salole EG. Estradiol. InAnalytical profiles of drug substances 1986 Jan 1 (Vol. 15, pp. 283-318). Academic Press.
Robinson M. The pharmacodynamics and pharmacokinetics of proton pump inhibitors–overview and clinical implications. Alimentary pharmacology & therapeutics. 2004 Nov; 20:1-0.
Handelsman DJ. Androgen physiology, pharmacology, use and misuse. Endotext [Internet]. 2020 Oct 5.
Adetuyi BO, Olajide PA. Pharmacological and therapeutic potential of ginger in the management of neurodegenerative disorders.
VINOTH D. Professor & HOD.
Szidónia F. Mechanism of action and neuroprotective potential of estradiol and new non-genomic estrogen-like signaling activators (Doctoral dissertation, University of Pécs (Hungary)).
Sivasankaran S. A Study on the Use of Poly (L-Lactic Acid) in Long-Term Controlled Release of Levonorgestrel for Contraception. University of the Sciences in Philadelphia; 2021.
Akombaetwa N, Ilangala AB, Thom L, Memvanga PB, Witika BA, Buya AB. Current advances in lipid nanosystems intended for topical and transdermal drug delivery applications. Pharmaceutics. 2023 Feb 15;15(2):656.
Osma?ek T, Froelich A, Jadach B, Tatarek A, Gadzi?ski P, Falana A, Grali?ska K, Ekert M, Puri V, Wroty?ska-Barczy?ska J, Michniak-Kohn B. Recent advances in polymer-based vaginal drug delivery systems. Pharmaceutics. 2021 Jun 15;13(6):884.
Bhatia M, Devi S. Co-crystallization: a green approach for the solubility enhancement of poorly soluble drugs. CrystEngComm. 2024;26(3):293-311.
Than YM. Formulation development of extended and immediate release tablets using extrusion-based 3d printing technology.
Nippe S. Injectable drug delivery systems for steroids (Doctoral dissertation).
Bhattacharya P, Saha A, Basak S. Discovery of nano-piperolactam A: a nonsteroidal contraceptive lead acting through down-regulation of interleukins. Nanomedicine: Nanotechnology, Biology and Medicine. 2019 Jun 1; 18:347-58.
Walters KA, Lane ME. Dermal and transdermal drug delivery systems: an overview and recent advancements. Dermal Drug Delivery. 2020 Jan 21:1-60.
Osma?ek T, Froelich A, Jadach B, Tatarek A. Gadzi nski. Drug Deliv. 2016; 23:550-63.
Verdan M, Taveira I, Lima F, Abreu F, Nico D. Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022). Expert Opinion on Therapeutic Patents. 2023 Mar 4;33(3):137-50.
Hameedat F, Hawamdeh S, Alnabulsi S, Zayed A. High performance liquid chromatography (HPLC) with fluorescence detection for quantification of steroids in clinical, pharmaceutical, and environmental samples: a review. Molecules. 2022 Mar 10;27(6):1807.
Hermans A, Abend AM, Kesisoglou F, Flanagan T, Cohen MJ, Diaz DA, Mao Y, Zhang L, Webster GK, Lin Y, Hahn DA. Approaches for establishing clinically relevant dissolution specifications for immediate release solid oral dosage forms. The AAPS journal. 2017 Nov; 19:1537-49.
Zhang Z. Application of Biorelevant Dissolution Method for Intrauterine Devices (Doctoral dissertation, University of Pittsburgh).
Shargel L, Kanfer I. Generic drug product development. DRUGS AND THE PHARMACEUTICAL SCIENCES. 2014 Oct 31; 204:204.
Jange CG, Wassgren CR, Ambrose K. The significance of tablet internal structure on disintegration and dissolution of immediate-release formulas: A review. Powders. 2023 Feb 17;2(1):99-123.
Singh GR. Design, Development and Evaluation of Controlled-Release Formulation of Freely Water-Soluble Drugs (Doctoral dissertation, Institute of Pharmacy, Nirma University, A'bad).
Stone J, Mitrofanis J, Johnstone DM, Falsini B, Bisti S, Adam P, Nuevo AB, George-Weinstein M, Mason R, Eells J. Acquired resilience: an evolved system of tissue protection in mammals. Dose-Response. 2018 Dec 27;16(4):1559325818803428.
Osma?ek T, Froelich A, Jadach B, Tatarek A, Gadzi?ski P, Falana A, Grali?ska K, Ekert M, Puri V, Wroty?ska-Barczy?ska J, Michniak-Kohn B. Recent advances in polymer-based vaginal drug delivery systems. Pharmaceutics. 2021 Jun 15;13(6):884.
Guideline IH. Bioequivalence for immediate-release solid oral dosage forms M13A. Draft version endorsed on. 2022 Dec 20;20.
Zhao JZ, Lin JJ, Yang HY, Zhang W, Huang XF, Huang YP. Effects of oral contraceptives and metformin on the outcome of in vitro maturation in infertile women with polycystic ovary syndrome. Journal of Women's Health. 2010 Feb 1;19(2):261-5.
Zheng X, Guo T, Wu F, Shen L, Lin X. Sustained-Release Drug Delivery Systems of Chinese Medicines. Novel Drug Delivery Systems for Chinese Medicines. 2021:49-76.
Berry C, Morrow A, Abraham G, Hoole S, Greenwood J, Arnold J, Shanmuganathan M, Ferreira V, Rakhit R, Galasko G, Sinha A. Precision Pharmacotherapy With Zibotentan in Microvascular Angina: a randomized, placebo-controlled, cross-over trial.
Khobragade DS, Agrawal SS, Potbhare MS. Pharmacokinetic Considerations for Controlled-release Dosage Forms. Novel Drug Delivery Systems (Part 1). 2024 Dec 5:39.
Song J, Xu Z, Xie L, Shen J. Recent Advances in Studying In Vitro Drug Permeation Across Mucosal Membranes. Pharmaceutics. 2025 Feb 14;17(2):256.
Fernandes EA, Oudtshoorn JV, Tam A, González LC, Aurela EG, Potthast H, Mettke K, Kuribayashi R, Shimojo K, Kasuga M, Morales L. The bioequivalence study design recommendations for immediate-release solid oral dosage forms in the international pharmaceutical regulators programme participating regulators and organisations: differences and commonalities. Journal of Pharmacy & Pharmaceutical Sciences. 2024 Mar 21; 27:12398.
Diehl DL, Tierney WM, Adler DG, Conway JD, Farraye FA, Kantsevoy SV, Kaul V, Kethu SR, Kwon RS, Mamula P, Pedrosa MC. The role of the US Food and Drug Administration in device evaluation and monitoring. Gastrointestinal Endoscopy. 2010 Jul 1;72(1):5-10.
Durán CE, Riera-Arnau J, Abtahi S, Pajouheshnia R, Hoxhaj V, Gamba M, Alsina E, Martin-Perez M, Garcia-Poza P, Llorente-Garcia A, Gonzalez-Bermejo D. Impact of the 2018 revised Pregnancy Prevention Programme by the European Medicines Agency on the use of oral retinoids in females of childbearing age in Denmark, Italy, Netherlands, and Spain: an interrupted time series analysis. Frontiers in Pharmacology. 2023 Aug 17; 14:1207976.
Sardella M, Costanzo L. The 7th European Pharmacovigilance Congress: speaker abstracts.
Marathe PA, Kamat SK, Tripathi RK, Raut SB, Khatri NP. Over-the-counter medicines: Global perspective and Indian scenario. Journal of postgraduate medicine. 2020 Jan 1;66(1):28-34.

Shivshankar Nagrik

Corresponding author

M. Pharm, Department of Pharmaceutics, Rajarshi Shahu College of Pharmacy, Buldhana, Maharashtra, India.